Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prognostic evaluation biomarker for kidney cancer as well as detection reagent and application thereof

A detection reagent and prognosis technology, applied in the field of renal cancer prognosis assessment biomarkers and detection reagents, can solve the problems that the value has not been reported in the literature, and the application research of lncRNA is few and so on.

Inactive Publication Date: 2017-12-19
NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still very little research on the application of lncRNA in serological markers
The value of lncRNA as a serological prognostic marker for renal cancer has not been reported in the literature so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prognostic evaluation biomarker for kidney cancer as well as detection reagent and application thereof
  • Prognostic evaluation biomarker for kidney cancer as well as detection reagent and application thereof
  • Prognostic evaluation biomarker for kidney cancer as well as detection reagent and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1: Screening of lncRNA-ReCAL

[0050] In order to screen lncRNAs for predicting the prognosis risk of renal cancer, we first used the large-scale transcriptome sequencing data of clear cell renal cell carcinoma from three different ethnic groups in the world (America cohort from TCGA project, n = 530; Japan cohort from EGAS00001000509, n = 100; Europe cohort from ICGC project, n=91), combined with clinical prognosis information, univariate Cox regression analysis was used to screen out 29 lncRNAs that had a significant correlation with the prognosis of renal cell carcinoma. Then, we used the median expression value of each lncRNA as the boundary, divided each cohort into two groups with high and low expression, performed log-rank analysis, and finally screened out a lncRNA that was correlated with the overall survival of patients in the three kidney cancer cohorts. The lncRNA (ENSG00000238113) with a significant correlation with cancer rate, because this lncRNA ...

Embodiment 2

[0051] Example 2: Histological verification of lncRNA-ReCAL

[0052] We used long-term follow-up of 1908 patients with RCC from three independent cohorts (Changhai cohort (n=1326), Long March cohort (n=353), Nanjing cohort (n=229)) to detect lncRNA-ReCAL as an The efficacy of prognostic markers was verified. The expression level of lncRNA-ReCAL in tumor tissue was detected by Real time-PCR technology, and the median expression abundance was divided into two groups with high and low expression. The results showed that the tumor-specific survival rate of kidney cancer patients with high expression of lncRNA-ReCAL was lower (Changhai cohort: p figure 2 ), the time to tumor progression was shorter (Changhai cohort: p image 3 ). These results suggest that lncRNA-ReCAL may be used as a marker for the prognosis of patients with RCC.

Embodiment 3

[0053] Example 3: The value of lncRNA-ReCAL in evaluating the prognosis of early renal cancer

[0054] According to the SSIGN risk scoring system developed by the Mayo Clinic in the United States, we divided each cohort into 3 groups according to the tumor stage (stage), size (size), grade (grade) and necrosis [16]. Subgroups, namely SSIGN0-3 (low-risk group), SSIGN4-7 (medium-risk group), SSIGN>8 (high-risk group), carried out Kaplan-Meier curve analysis on each subgroup, found that in the low-risk group, lncRNA-ReCAL expression has the most significant discriminative ability for the prognosis of renal cancer (see Figure 4-6 , CSS; Changhai cohort log-rank p = 8.64E-20; Long March cohort log-rank p = 5.75E-5; Nanjing cohort log-rank p = 0.002; see Figure 7-8 , PFS; Changhai cohort log-rank p=1.94E-24; Longzheng cohort log-rank p=3.74E-7), while the predictive ability for the prognosis of high-risk renal cancer patients is poor (see Figure 4-6 , OS; Changhai cohort log-ra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a prognostic evaluation biomarker for kidney cancer as well as a detection reagent and application thereof, and provides application of IncRNA-ReCAL to preparation of the detection reagent or a kit for indicating prognosis of the kidney cancer. Further, the invention provides the kit for detecting IncRNA-ReCAL in blood serum; by detecting the blood serum of kidney cancer patients, IncRNA-ReCAL can be detected in the blood serum, and prognosis on the kidney cancer patients who have high content of IncRNA-ReCAL in the blood serum is worse. According to the prognostic evaluation biomarker for the kidney cancer as well as the detection reagent and the application thereof disclosed by the invention, a new clinical means is provided for prognostic evaluation on serology of the kidney cancer, and the prognostic evaluation biomarker has a significant clinical meaning and a popularization and application prospect.

Description

technical field [0001] The invention relates to the technical field of medical biological detection, in particular to a renal cancer prognosis evaluation biomarker, a detection reagent and an application thereof. Background technique [0002] RCC is a highly heterogeneous tumor, and even patients with the same clinical stage have significantly different prognosis. After radical resection of early renal cancer patients, 20-30% of patients will eventually develop recurrence and metastasis, and the 5-year survival rate of advanced renal cancer patients is less than 30%. If an accurate and effective prognostic assessment can be performed on patients with early renal cell carcinoma, it will be able to assist clinical practice selection, guide patients' reexamination cycle, and achieve early detection and early treatment of tumor progression. Therefore, it is of great clinical significance to screen and identify new and effective prognostic molecular markers for RCC, especially e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q2600/118C12Q2600/178
Inventor 曲乐陈程何昊玮
Owner NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com